Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload

Svetlana Slavic1, Kristopher Ford1, Magalie Modert1, Amarela Becirović1, Stephan Handschuh2, Andreas Baierl1, Nejla Katica1, Ute Zeitz1, Reinhold G. Erben1 & Olena Andrukhova1

Left ventricular hypertrophy (LVH) ultimately leads to heart failure in conditions of increased cardiac pre- or afterload. The bone-derived phosphaturic and sodium-conserving hormone fibroblast growth factor-23 (FGF23) and its co-receptor Klotho have been implicated in the development of uremic LVH. Using transverse aortic constriction (TAC) in gene-targeted mouse models, we examine the role of Fgf23 and Klotho in cardiac hypertrophy and dysfunction induced by pressure overload. TAC profoundly increases serum intact Fgf23 due to increased cardiac and bony Fgf23 transcription and downregulation of Fgf23 cleavage. Aldosterone receptor blocker spironolactone normalizes serum intact Fgf23 levels after TAC by reducing bony Fgf23 transcription. Notably, genetic Fgf23 or Klotho deficiency does not influence TAC-induced hypertrophic remodelling, LV functional impairment, or LV fibrosis. Despite the profound, aldosterone-mediated increase in circulating intact Fgf23 after TAC, our data do not support an essential role of Fgf23 or Klotho in the pathophysiology of pressure overload-induced cardiac hypertrophy.

Left ventricular hypertrophy (LVH) occurs together with reactive interstitial and perivascular fibrosis as an adaptive response aimed to reduce wall stress during increased pre- or afterload. However, prolonged increases in workload lead to cardiomyocyte death, replacement fibrosis, and transition to heart failure (HF). Both LVH and cardiac fibrosis are strong and independent predictors of cardiovascular mortality. To reduce the incidence of HF in risk patients, a better understanding of the mechanisms underlying the pathophysiology of hypertrophy is needed. In this context, augmented fibroblast growth factor-23 (FGF23) signalling as well as Klotho deficiency have been implicated as novel mediators of heart hypertrophy in the general population and in patients with chronic kidney disease (CKD).

FGF23 is a phosphaturic, Na+ and Ca2+-preserving hormone with an important regulatory function on 1,25(OH)2D3 metabolism. FGF23 is normally mainly synthesized by osteocytes and osteoblasts, but under certain pathological conditions its synthesis can be increased also in extra-osseous tissues, such as heart, spleen, calcified coronary arteries, and kidney. At physiological concentrations, binding of FGF23 to FGF receptors (FGFR) on target cells is mediated by αKlotho (further Klotho), a transmembrane protein which associates with FGFRs to increase their binding affinity for FGF23. Klotho also exists in a soluble form, which is generated by shedding of transmembrane Klotho or by alternative splicing of the Klotho gene. The co-receptor function of Klotho is essential for the renal actions of FGF23, but the role of Klotho in the cardiovascular system is controversial. In the heart, expression of Klotho is limited to the sinoatrial node. Although a protective role of soluble Klotho in the development of LVH has been reported in animal models, clinical studies failed to confirm an association between soluble Klotho and cardiovascular mortality in patients with normal renal function. Elevated serum FGF23 levels were found to be strongly associated with LVH in patients with reduced kidney function. On the other hand, cardiac dysfunction and hypertrophy are not universal findings in patients with...
FGF23-related hypophosphatemic rickets characterised by chronically elevated FGF23. Therefore, the role of FGF23 and Klotho in the pathophysiology of heart hypertrophy is still unclear.

In vitro, FGF23 induced cardiomyocyte (CM) hypertrophy by Klotho-independent binding to FGF4, activating the pro-hypertrophic phospholipase Cγ/calcineurin/nuclear target of activated T cells (NFAT) signalling pathway. In vitro experimental evidence of FGF23-mediated LVH is mainly based on studies performed in experimental CKD models. Driven by deterioration of renal function, FGF23 serum levels rise progressively in CKD. However, the pathophysiology of CKD is complex, and characterized by the presence of additional factors such as electrolyte disturbance, hypervolemia and hypertension. We recently reported that FGF23 increases renal calcium and sodium reabsorption, which may favour vessel calcifications, leading to increased afterload, and may increase preload due to renal sodium preservation and subsequent hypervolemia. Thus, FGF23-mediated hypertrophy in CKD is probably multifactorial rather than solely caused by a direct pro-hypertrophic action on cardiomyocytes.

Due to the early lethality of Fgf23 deficient mice, a direct proof that FGF23 plays an essential role in mediating cardiac hypertrophy is missing. Fgf23−/− and Klotho−/− mice suffer from intoxication with 1,25(OH)2D3 due to the lack of FGF23-mediated inhibition of renal 1α-hydroxylase, resulting in hypercalcemia and hyperphosphatemia, which are responsible for the premature aging-like phenotype and the early mortality. To overcome this, we generated Fg23−/−/VDRΔΔ and Klotho−/−/VDRΔΔ compound mutants by crossing Fg23−/− and Klotho−/− mice with mice expressing a non-functioning vitamin D receptor (VDRΔΔ)26–28. To normalize calcium and phosphate homeostasis in VDRΔΔ mice, all mice were maintained on a so-called rescue diet, enriched with calcium, phosphorous, and lactose. Transverse aortic constriction (TAC) is the most commonly used model of pressure overload-induced cardiac hypertrophy. To test the hypothesis that Fg23 and Klotho play an essential role in the development of cardiac hypertrophy induced by increased afterload, we induced TAC in wild-type (WT), VDRΔΔ, Fg23−/−/VDRΔΔ, and Klotho−/−/VDRΔΔ mice. In addition, we investigated the possible mechanisms of the TAC-induced upregulation of cardiac and bony Fgf23 production. We found that neither Fgf23 nor Klotho deficiency modulates cardiac hypertrophy induced by pressure overload.

**Results**

**Increased cardiac afterload up-regulates Fgf23 expression.** We previously reported increased serum intact Fgf23 levels in experimental myocardial infarction models. Therefore, we first examined whether increased afterload also affects circulating Fgf23 levels. TAC was performed in WT animals using two different pressure grades by ligating the aorta to the lumen of a 24-gauge (OD 0.57 mm) or a 27-gauge (OD 0.41 mm) needle. Left ventricular (LV) fractional shortening (FS) decreased (Suppl. Figure 1a), while heart/body weight ratio and lung oedema increased in parallel with the increased afterload in TAC animals compared to sham, 4 weeks post-surgery (Fig. 1a,b and Suppl. Figure 1b respectively). Interestingly, serum intact Fgf23 levels were also elevated in an afterload dependent manner (Fig. 1c). Using a time course study, we found a profound up-regulation of circulating intact Fgf23 levels within 24 hours after TAC, which was sustained for at least 4 weeks post-surgery (Suppl. Figure 1c).

To define the site of increased Fgf23 production, we analysed transcript levels of Fgf23 mRNA in the heart and in bone, 4 weeks post-surgery. TAC significantly increased cardiac Fgf23 gene expression (Fig. 1d). Albeit statistically non-significant, a tendency for increased Fgf23 expression was also observed in bone of TAC animals, relative to sham. Overall, bone exhibited significantly higher transcript levels of Fgf23 after TAC compared to the heart, suggesting that upregulated bony production may largely account for the increased circulating Fgf23 levels during pressure overload. In an attempt to further explore the discrepancy between highly elevated serum intact Fgf23 and only moderate induction of cardiac Fgf23 expression after TAC, we analysed molecules known to be important for the regulation of Fgf23 cleavage. Indeed, pressure overload dramatically reduced the occurrence of cleaved Fgf23 in serum (Fig. 1e). Consistent with a decreased cleavage of Fgf23, we found significantly increased cardiac expression of GalNT3 (N-Acetylgalactosaminyl-transferase 3), an enzyme O-glycosylating and thereby stabilising FGF2330, 31, 4 weeks post-TAC (Fig. 1f). In contrast, bony expression of GalNT3 was not changed after TAC (data not shown). Cardiac expression of Famm20c and Furin, both promoting Fg23 cleavage, remained unchanged after TAC (Fig. 1f). Collectively, these data suggest that reduced Fgf23 cleavage may contribute to increased intact Fgf23 concentrations in the heart during pressure overload stress.

Next, we analysed serum biochemistry to test whether mineral ion alterations were associated with the increased serum Fgf23 levels induced by pressure overload. However, serum levels of phosphate, calcium, sodium, potassium, and iron were not significantly changed as compared to sham animals, 4 weeks after TAC. This excludes the possibility that increased phosphate and/or reduced iron levels are driving Fgf23 secretion following TAC. Mild, but significant increases in serum creatinine, urea and alkaline phosphatase levels were noted in TAC mice, 4 weeks post-surgery (Suppl. Table 1).}

**The pressure overload-induced increase in serum Fgf23 levels is mediated by aldosterone.** Since aldosterone was shown to stimulate FGF23 expression in vitro, we next examined serum aldosterone levels in sham and TAC mice. Indeed, serum aldosterone levels were significantly increased in TAC animals, and followed a similar afterload-dependent pattern, compared with circulating intact Fgf23 levels (Fig. 2a). To investigate the role of aldosterone in the upregulation of Fgf23 secretion after TAC, we orally treated WT animals with mineralocorticoid receptor inhibitor spironolactone over 2 weeks post-TAC. Spironolactone treatment increased urinary sodium excretion in TAC mice, whereas urinary potassium was not significantly changed (Suppl. Figure 2a,b). Serum sodium and potassium concentrations remained unchanged (data not shown). Renal function as measured by glomerular filtration rate was similarly reduced in all TAC animals, independent of spironolactone treatment (Suppl. Figure 2c). The administered dosage of spironolactone did not alter mean aortic pressure (Fig. 2i). Interestingly, spironolactone suppressed the rise in serum Fgf23 levels following TAC, but had
no influence on basal Fgf23 levels in Sham mice (Fig. 2b). To define the target organ of the suppressive effect of spironolactone treatment on circulating intact Fgf23 levels in TAC mice, we analysed Fgf23 mRNA abundance in heart and bone. Spironolactone treatment did not influence transcription of Fgf23 in the heart, but significantly reduced transcription of Fgf23 in bone, 2 weeks after TAC (Fig. 2c). Taken together, these data suggest that the pressure overload-induced increase in bony Fgf23 expression is mainly driven by increased aldosterone secretion in TAC mice. To our surprise, we did not observe a rescue of heart hypertrophy, 2 weeks after spironolactone treatment, despite reduced serum Fgf23 levels (Fig. 2d–f). Parameters of cardiac hypertrophy such as increased heart/body weight ratio, increased cardiomyocyte size and LV wall thickness, reduced fractional shortening, and lung oedema remained unchanged after spironolactone treatment (Fig. 2d–h and Suppl. Figure 2d,e), questioning the importance of increased systemic Fgf23 for the development of heart hypertrophy induced by pressure overload.
Genetic deletion of Fgf23 or Klotho does not modulate afterload-induced cardiac hypertrophy and pro-hypertrophic signalling.

To address the question whether local, paracrine Fgf23 signalling may be involved in the hypertrophic changes during pressure overload, we used a model of genetic deletion of Fgf23 in the TAC model. In addition, since Klotho was previously shown to protect against uraemia-induced heart hypertrophy, we investigated whether FGF23-independent Klotho signalling may be involved in the pathophysiology of TAC-induced LV hypertrophy. Because genetic disruption of vitamin D signalling rescues the lethal phenotype of Fgf23 and Klotho null mice, we used Fgf23−/−/VDRΔΔ and Klotho−/−/VDRΔΔ compound mutants to assess the role of Fgf23 and Klotho in the pathophysiology of cardiac hypertrophy. Mice with a non-functioning VDR (VDRΔΔ) were used as controls.

To address the question whether a VDR deficient background influences the response of mice to TAC, we first assessed the TAC-induced increase in serum and cardiac levels of Fgf23 in the different genotypes. Circulating intact Fgf23 and cardiac Fgf23 protein expression did not differ in sham WT, VDRΔΔ and Klotho−/−/VDRΔΔ mice on rescue diet, and were profoundly increased after TAC in all genotypes to levels beyond 1,000 pg/mL (data not shown). Importantly, there was no difference in the hypertrophic response of
VT and VDR deficient mice to TAC (Suppl. Figure 3a–c). Moreover, a 5-day i.p. treatment with recombinant FGF23 (rFGF23) induced a similar degree of LV hypertrophy and a similar increase in mean arterial pressure in WT and VDR mutant mice (Suppl. Figure 3d–f). Taken together, these data demonstrate that a VDR deficient background neither blunts the TAC-induced increase in FGF23 expression nor the prohypertrophic actions of FGF23, and does not modulate the hypertrophic response to TAC.

Aortic pressure after TAC in the ascending aorta proximal to the ligation was similar in all groups confirming that the same grade of pressure-overload was induced in all three genotypes (Suppl. Table 2). Survival rate after the TAC procedure was similar in Fgfg23−/−/VDRΔΔ and Klotho−/−/VDRΔΔ mutant mice compared to VDRΔΔ mice (Suppl. Figure 4a). In addition, the TAC-induced changes in heart/body weight ratio, heart weight/femur length ratio, cardiomyocyte size, LV wall thickness, lung oedema, expression of the molecular hypertrophy marker Bnp, LV systolic and diastolic function, and LV mass and size were similar in mice of all genotypes (Fig. 4, Suppl. Figure 4, and Suppl. Table 2). Heart rate tended to be higher in TAC mice of all genotypes relative to Sham controls, but this effect reached statistical significance only in VDR mutant mice, but not in Fgfg23−/−/VDRΔΔ and Klotho−/−/VDRΔΔ mutant mice (Suppl. Figure 4c). Neither did the absence of Fgfg23 in Fgfg23−/−/VDRΔΔ animals protect against cardiac hypertrophy, nor did deletion of Klotho lead to further exacerbation of the TAC-induced hypertrophic phenotype, relative to VDRΔΔ controls.

These results suggest that factors other than FGF23 are essentially mediating the hypertrophic response during pressure-overload. Previously it was shown that FGF2 signalling is necessary for hypertrophy development during TAC39. We also found increased cardiac Fgfg2 mRNA expression in WT mice, 2 weeks (Suppl. Figure 5a) and 4 weeks (not shown) after TAC. In addition, pressure overload increased cardiac Fgfg2 mRNA abundance in VDRΔΔ, Fgfg23−/−/VDRΔΔ, and Klotho−/−/VDRΔΔ mice, 4 weeks post-surgery (Suppl. Figure 5b). Neither spironolactone treatment nor Fgfg2 or Klotho deficiency affected the TAC-induced rise in cardiac Fgfg2 expression, which is in accordance with unchanged hypertrophy development in these mice (Suppl. Figure 5, Figs 2 and 4). To test the possible involvement of ERK1/2 signalling in the TAC-induced hypertrophy, we analysed the activation of ERK1/2 after TAC. However, phosphorylation of ERK1/2 in cardiac tissue remained unchanged, 2 weeks after TAC or after spironolactone treatment (Suppl. Figure 5c), indicating that cellular signalling pathways other than ERK1/2 mediate hypertrophy during the early phase of pressure overload. On the contrary, TAC activated cardiac calcineurin/NFAT signalling, as evidenced by reduced expression of pNFAT in histological sections, and by increased transcription of its target gene regulator of calcineurin 1 (rCAN1) (Suppl. Fig. 6). In addition, spironolactone treatment did not affect pNFAT expression in cardiomyocytes of Sham and TAC mice, 2 weeks post-surgery (Suppl. Fig. 6). Similarly, Fgfg23 and Klotho deficiency had no influence on cardiac calcineurin/NFAT signalling as shown by similarly increased cardiac rCAN1 gene expression in all TAC animals (Suppl. Fig. 6). Collectively, these data indicate that neither Fgfg23 nor Klotho deficiency nor spironolactone treatment modulate afterload-induced cardiac pro-hypertrophic signalling.

Afterload-induced cardiac fibrosis develops independent of Fgfg23 and Klotho, and is associated with upregulated cardiac FGF receptor-1 and -3 expression. Interstitial fibrosis is one of the hallmarks of LV hypertrophic cardiomyopathy. An adverse role of FGF23 in promoting cardiac fibrosis was recently suggested34. We found that 4 weeks after TAC, interstitial fibrosis as well as type I collagen (CoIα)
Figure 4. Loss of Fgf23 or Klotho does not modulate afterload-induced cardiac hypertrophy. (a) Heart/body weight ratio and (b) lung/body weight ratio (n = 6–10). (c) Cardiac mRNA expression of brain natriuretic peptide (Bnp, n = 5–6). (d) Left: Representative FITC-labelled wheat germ agglutinin (WGA)-stained sections (Scale bar: 50 µm). Right: Quantification of mean cardiomyocyte size after FITC-WGA staining (n = 6–9). (e) Fractional shortening, left ventricular wall thickness and diastolic functional parameter (E/A ratio) measured by echocardiography 4-weeks post-surgery (n = 6–9). (f) Representative echocardiograms of M-mode and pulsed-wave Doppler analysis in sham VDRΔ/Δ, Fgf23−/−/VDRΔ/Δ and Klotho−/−/VDRΔ/Δ mice. Data in (a–e) presented as mean ± SEM for VDRΔ/Δ, Fgf23−/−/VDRΔ/Δ and Klotho−/−/VDRΔ/Δ mice after sham and TAC (27 G) surgery. *p < 0.05 vs. sham control of the same genotype.
mRNA expression were increased in the LV and septum in all genotypes (Fig. 5a–c). Interestingly, Klotho−/−/VDRΔΔ mutants showed reduced cardiac Col1α mRNA expression levels compared to VDRΔΔ and Fgf23−/−/VDRΔΔ mutant mice following TAC. Therefore, factors other than Fgf23 seem to be involved in cardiac pro-fibrotic changes upon TAC.

Recently, it was shown in a CKD-mediated cardiac hypertrophy model that FGF23 exerts its pro-hypertrophic action in cardiomyocytes by Klotho-independent signalling through FGFR4. To obtain further insight into potential FGFR-mediated signalling mechanisms in TAC-induced cardiac hypertrophy, we investigated mRNA expression of Fgfr1, Fgfr3 and Fgfr4 in WT, VDRΔΔ, Fgf23−/−/VDRΔΔ, and Klotho−/−/VDRΔΔ mice, 4 weeks after TAC. In our experimental settings, cardiac mRNA expression of Fgfr3 and Fgfr1 were 100- and 250-fold higher compared to Fgfr4 mRNA expression in WT Sham mice (Suppl. Fig. 7). TAC consistently increased Fgfr1

**Figure 5.** Fgf23 and Klotho deficiency do not protect from afterload-induced cardiac fibrosis. (a) Cardiac relative mRNA expression of Col1α (n = 5–6). (b) Quantification of fibrosis after picrosirius red staining (n = 6–9). (c) Representative images of total collagen in cardiac sections after picrosirius red staining (Scale bar: 100 µm). (d–f) Effect of pressure overload and Fgf23 or Klotho deficiency on cardiac Fgf receptor mRNA expression (n = 5–6). Data in (a–f) are from VDRΔΔ, Fgf23−/−/VDRΔΔ and Klotho−/−/VDRΔΔ mice, 4-weeks after sham and TAC (27 G) surgery. Data are mean ± SEM, in (a,b) *p < 0.05 vs. sham control of the same genotype; in (a) #p < 0.05 vs. VDRΔΔ and Fgf23−/−/VDRΔΔ mice, in (d–f) *p < 0.05.
and Fgf23 mRNA expression in all investigated genotypes (Fig. 5d,e and Suppl. Fig. 7). In contrast, Fgf4 mRNA expression was significantly increased after TAC in Fgfr3+/−/VDRΔΔ and VDR+/Δ mice but was unchanged in WT and Klotho−/−/VDRΔΔ mice (Fig. 5 and Suppl. Fig. 7). The robust TAC-induced upregulation in Fgfr1 and Fgf23 mRNA abundance across all genotypes suggests that augmented FGFR signalling may be an important component of the cardiac response to increased afterload. However, the role of specific FGFRs in this signalling network is only poorly understood.

Discussion

FGF23 and Klotho have emerged as potential novel players in the pathophysiology of LVH. In the present study, we induced TAC in mice with a genetic deletion of Fgfr23 and Klotho to study their role in pressure overload-induced LVH. We demonstrate that TAC profoundly increases serum levels of intact Fgfr23, augments cardiac mRNA and protein expression of Fgfr23, increases cardiac transcription of the Fgfr23-stabilizing enzyme GalNT3, and increases Fgf23 transcription in bone by an aldosterone-driven mechanism. Finally, we provide evidence that Fgfr23 and Klotho deficiency does not modulate the development of LVH and cardiac dysfunction following TAC.

Clinical evidence suggests Fgfr23 as a strong predictor of adverse cardiovascular events in CKD patients. A positive correlation between FGF23 levels and cardiovascular outcomes was also shown in patients with established cardiovascular disease. However, studies in community-based non-CKD populations are less consistent, and the association between circulating FGF23 and major cardiovascular events was attenuated after correction for glomerular filtration rate, or was even absent. To shed more light on the possible pathological role of FGF23 in the development of hypertrophy and heart failure we employed TAC, a pressure overload-induced hypertrophy model. We demonstrated that serum levels of intact Fgfr23 (iFgfr23) rose dramatically after pressure overload. Serum levels of iFgfr23 are regulated both on the transcriptional level and by posttranslational regulation of FGF23 cleavage. Furin and furin-like proteases cleave iFgfr23 into inactive fragments, a process which is inhibited by GalNT3-mediated O-glycosylation at the cleavage site. Conversely, phosphorylation of Fgfr23 near the cleavage site by Fam20c prevents O-glycosylation, and facilitates furin-mediated cleavage. Here, we report the novel finding of pressure overload-induced upregulation of GalNT3 gene expression in the heart. This finding may not only be relevant for increasing local levels of iFgfr23, but also for posttranslational modification and function of other proteins.

Pressure overload enhanced Fgfr23 gene transcription in heart and bone in our study. So far, several factors have been shown to regulate expression of the Fgfr23 gene such as phosphate, 1,25(OH)2D3, parathyroid hormone, inflammation, hypoxia, and iron deficiency. However, it remains an open question why bone and heart respond to local cardiac stress with an increase in Fgfr23 transcription. While the cardiac stimulus is still unknown, our study has identified aldosterone as an important stimulator of bony Fgfr23 transcription after TAC, because mineralocorticoid receptor blockade with spironolactone normalised serum iFgfr23 levels and bone Fgfr23 gene expression after TAC. In agreement with our finding, serum aldosterone levels correlated with circulating Fgfr23 levels in patients with non-ischemic cardiac disease, and aldosterone increased Fgfr23 production in vitro and in animal models. Notably, spironolactone did not have any effect on serum and mRNA levels of Fgfr23 in control mice, indicating that aldosterone is not involved in the regulation of basal Fgfr23 production. In line with that, spironolactone treatment did not reduce high Fgfr23 plasma concentrations in Klotho deficient mice. Interestingly, we did not observe any effect of spironolactone on cardiac Fgfr23 mRNA expression. Therefore, it is conceivable that different, tissue specific mechanisms are involved in the regulation of cardiac and bony Fgfr23 expression.

The physiological role of Klotho signalling in the heart is still controversial. Previous reports have shown that Klotho deficiency results in elevated iFgfr23 levels which may per se induce LVH in a Klotho-independent fashion, that soluble Klotho is protective in uremic and isoproterenol-induced cardiomyopathy, and that Klotho deficiency aggravates the stress-induced hypertrophic response due to dysregulation of cardiac TRPC6 channels. However, our study did not show any evidence of a negative effect of Klotho deficiency on cardiac phenotype and on development of LVH during pressure overload. One of the possible explanations for this discrepancy is that Klotho−/−/VDRΔΔ mice on rescue diet used in the current study displayed no mineral disturbance, whereas others used Klotho−/− mice, characterised by 1,25(OH)2D3-mediated hypercalcaemia and hyperphosphatemia.

In our study we provided evidence that Fgfr23 is not essentially mediating pressure-induced cardiac hypertrophy in a TAC model, using two independent approaches: i) by spironolactone-induced Fgfr23 suppression in WT mice, and ii) by genetic deletion of Fgfr23 in Fgfr3+/−/VDRΔΔ mice. In both approaches, TAC-induced LVH developed independently of the presence or absence of Fgfr23, and was not modulated by high or normal circulating iFgfr23 levels. In the light of the solid evidence from clinical and experimental studies showing a strong association between circulating iFgfr23 and LVH in CKD, this is a perplexing finding. However, there are several explanatory scenarios for this apparent discrepancy. First, the specific type of cardiac load influences the type of cardiac hypertrophy in CKD and during pressure-overload. CKD is a condition where volume overload is a major contributor of cardiovascular complications. Fluid retention predicted risk of cardiovascular morbidity and mortality in CKD patients better than hypertension. Differential signalling pathways are activated during volume overload-induced LVH compared to pressure overload-induced LVH, suggesting involvement of different pro-hypertrophic mediators. Secondly, the most compelling mechanistic explanation of FGF23’s involvement in CKD-related hypertrophy is based on studies where FGFR4 but not FGF23 were selectively targeted by monoclonal antibodies. Therefore, it remains unknown whether signalling molecules other than FGF23 may signal through FGFR4 in order to induce LVH in CKD. An essential role of paracrine FGF2 has been demonstrated in pressure overload-induced cardiac hypertrophy, as genetic deletion of Fgf2 protected from hypertrophic changes. In the current study, we confirmed increased cardiac Fgf2 transcription in TAC mice. Thus, we suggest
that increased FGF23 levels are not necessarily essential for the hypertrophic response in the presence of other molecules which may have a competing affinity for the same receptor, leading to the signalling switch associated with LVH. Changes in the pattern of FGF receptor expression may facilitate such a switch in cardiac tissue during pressure overload. Unlike in CKD, where gene expression of FGFR4 is stimulated in the myocardium, we found increased Fgfr1 and Fgfr3, but unchanged Fgfr4 cardiac mRNA expression in our TAC pressure overload model. Others also reported that Fgfr1 and Fgfr3 are the most abundant FGFRs in the heart. Further studies will be necessary to disentangle the differences in FGFR signalling between the different cardiac hypertrophy models.

A limitation of the current study is that the Fgfr3- and Klotho- deficient animal models were on a VDR deficient genetic background to avoid early lethality. In addition, it is necessary to feed the VDR−/− mice a chow enriched in phosphate and calcium (rescue diet) in order to avoid hypocalcaemia in these mice. However, our data indicate that absence of a functioning VDR does not blunt the pro-hypertrophic actions of FGF23 in vivo, and does not interfere with the TAC-induced increase in circulating Fgf23 or with the TAC-induced cardiac hypertrophy. Nevertheless, we cannot completely rule out an interaction between vitamin D and Fgfr3 signalling in the heart.

Collectively, the results of the current study provide novel insights into the regulation and the role of Fgf23 in pressure overload-induced cardiac hypertrophy. Although we found a profound upregulation of circulating Fgf23 as well as of cardiac and bony Fgf23 transcription after TAC, our data do not support an essential role of Fgf23 or Klotho in the pathophysiology of pressure overload-induced cardiac hypertrophy. Thus, the pathophysiological role of elevated Fgf23 levels during pressure overload remains to be clarified.

Methods

Animals. All animal procedures were undertaken in accordance with European guidelines for animal experiments (EU RL 2010/63/EU) and approved by the Ethical Committees of the University of Veterinary Medicine Vienna and of the Austrian Federal Ministry of Science, Research and Economy. Adult male WT, VDR−/−, Fgfr3−/−/VDR−/−, and Klotho−/−/VDR−/− mice were bred and genotyped as previously described. Mice were maintained on rescue diet (Sniff™) enriched in calcium (2.0%), phosphorous (1.25%) and lactose (20%) in order to normalize mineral homeostasis in VDR-ablated mice. All animals were kept in groups of 2–7 mice at 22–24°C and a 12 h light/12 h dark cycle with free access to tap water and food.

A group of male 3-month-old WT and VDR−/− mutant mice (n = 3–4 per group) received daily intraperitoneal injections of vehicle (phosphate-buffered saline with 2% DMSO) or 10 µg recombinant human FGF23 R176/179Q (rFGF23, kindly provided by Dr. Moosa Mohammadi, New York University School of Medicine) per mouse.

Transverse aortic constriction. Transverse aortic constriction (TAC) or sham surgeries were performed in 3–4-month-old male mice under general anaesthesia induced with ketamine/medetomidine (100/0.25 mg/kg i.p.). Animals were endotracheally intubated, and ventilated with a tidal volume of 200 µl and a frequency of 200 breathing cycles per min using a small animal ventilator (SAR-1000; CWE Incorporated). After sternotomy, a ligation was placed between the origins of the brachiocephalic and left common carotid arteries around a 24- or 27-gauge needle, using a 6–0 silk suture, followed by prompt removal of the needle. Because preliminary experiments demonstrated more robust cardiac hypertrophy development using ligation with a 27-gauge needle, all remaining experiments in the study were performed accordingly. Sham animals underwent the same procedure without the aortic ligation. Analgesic (buprenorphine 0.25 mg/kg s.c.) and antibiotic (enrofloxacin, 10 mg/kg s.c) were injected for 4 and 5 days, respectively. Animals were killed 2 or 4 weeks after surgery by exsanguination from the abdominal vena cava under ketamine/xylazine anaesthesia (70/7 mg/kg i.p.). Tissue and serum samples were harvested, flash frozen and stored at −80°C, or processed for histological analysis.

Spironolactone treatment. Some mice were randomized to treatment with spironolactone (20 mg/kg in 0.7% ethanol) or vehicle (0.7% ethanol) administered in 100 µl by daily gavage. Treatment started one day before TAC or sham surgery and was continued until the end of the study, 2 weeks post-surgery.

Transthoracic Doppler echocardiography. Echocardiography was performed 2 and 4 weeks after surgery using a 14 MHz linear transducer (Siemens Accuson s2000) under 1% isoflurane anaesthesia. Left ventricular (LV) wall thickness, internal dimensions and fractional shortening were evaluated in anatomic M-mode recorded in the short axis view at the papillary muscles level. Diastolic flow through the mitral valve was measured to evaluate LV diastolic function using pulsed-wave Doppler in the apical 4-chamber view. Success of the aortic constriction was evaluated from flow velocities measured in the thoracic aorta distal to the ligation. At least 5 cardiac cycles were averaged for each measured parameter.

Central arterial and cardiac pressure measurement. Aortic and cardiac pressures were assessed using a SPR-671NR pressure catheter (1.4 F, Millar Instruments, Houston, TX, USA). Central arterial pressure was measured by inserting the catheter into the ascending aorta via the carotid artery under 1.0% isoflurane anaesthesia. The catheter was then advanced into the LV for measurement of cardiac pressure parameters. Pressure traces were recorded over 5 min, and analysed using LabChart7 software.

Serum and urine biochemistry. Serum and urinary sodium, potassium, phosphorus, calcium, iron, and creatinine were analysed using a Cobas c111 analyser (Roche). Serum aldosterone (NovaTec), intact FGF23 (Kainos), and C-terminal Fgf23 (Immutopics) were assessed by commercially available ELISAs.

RNA isolation and quantitative RT-PCR. Total RNA was isolated from flash-frozen tissue after homogenization using TRI Reagent® Solution (Invitrogen). The concentration and purity of isolated RNA were determined spectrophotometrically (NanoDrop 2000; ThermoScientific). 1 µg of RNA was reverse transcribed (High
Capacity cDNA Reverse Transcription Kit; Applied Biosciences). Quantitative RT-PCR was performed on a Viia7 device (Applied Biosystems®) using the 5x Hot Firepol® Eva Green kit (Solis Biodyne). To exclude amplification of genomic DNA, primers were designed as exon spanning and their sequence is available upon request. A product melting curve analysis was performed to exclude primer dimerization and nonspecific amplification. All samples were measured in duplicate and expression values were normalized to ornithine decarboxylase antizyme 1 (Odz1) mRNA.

**Histological evaluation of cardiac hypertrophy and fibrosis.** Hearts were fixed in 4% paraformaldehyde for 24 h, embedded in paraffin and sectioned at a thickness of 5 μm. Fibrotic tissue was visualized by staining with picrosirius red according to a standard protocol. Collagen content was evaluated using ImageJ from the whole circumference of the left ventricle and septum at the level of the papillary muscles, and expressed as ratio of collagen-stained area to total muscle area of the left ventricle and septum. For the analysis of cardiomyocyte size, cardiac sections were stained with FITC-labelled wheat germ agglutinin. Cardiomyocyte size was evaluated using a semi-automated procedure by ImageJ in at least 800 cardiomyocytes from various regions of LV and septum. Fibrosis and cardiomyocyte size were each evaluated by 2 independent investigators in a blinded manner.

**Immunohistochemistry.** Antigen retrieval was performed by heating the de-paraffinised cardiac sections to 100 °C for 15 min in citrate buffer (pH 6). Sections were then treated for 30 min with blocking solution containing 10% goat serum and 0.02% Triton X in PBS to prevent unspecific antibody binding. Primary antibody anti-phospho-NFATc4 (rabbit polyclonal IgG, 1:100 in blocking solution, St John’s Laboratory) were incubated for 60 min at room temperature. After washing, secondary biotinylated antibody (1:500, Vector) was added for 60 min at room temperature. Signal was developed by incubation with streptavidin-peroxidase (KPL-HistoMark) followed by 3-amin-9-ethyl carbazole (AEC, Invitrogen) staining. Sections were counter-stained with haematoxylin.

**Western blotting.** Protein lysates from LV tissue were prepared using RIPA buffer according to standard protocols. Primary antibodies against FGF receptor 1 (FGFR1) (rabbit polyclonal IgG, D8E4, Cell Signalling) and GAPDH (Millipore) were used. After washing, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Amersham Life Sciences), and bound antibody was detected using ECL reagent (Bio Rad). Quantification of Western blots was performed using ImageJ software. Protein expression was normalized to the expression of GAPDH.

**Data Availability.** All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

**Statistical analysis.** Data are presented as mean ± SEM. Statistical analysis was performed using GraphPad Prism 6 and statistical software R version 3.2.3 (R Development Core Team, 2016). Comparisons between two groups were performed by two-sided t-test. Three- or more group comparisons within one genotype (WT) were performed using one-way ANOVA. In order to test for genotype-specific differences in TAC vs. sham surgery effects, two-way ANOVA models were used with the investigated parameter as dependent variable and genotype and surgery group as independent variables. For each genotype (VDRΔΔ, Fgf23−/−/VDRΔΔ and Klotho−/−/ VDRΔΔ) the mean parameter values in the TAC and SHAM surgery group and a 95% confidence interval for the difference of means were derived. Separate models were specified to compare genotypes, VDRΔΔ vs Fgf23−/−/VDRΔΔ and VDRΔΔ vs Klotho−/−/ VDRΔΔ. A potential genotype-specific difference in the surgery effect was assessed by testing for a significant interaction between genotype and surgery within the ANOVA model. Normality assumptions for confidence intervals and ANOVA residuals were assessed visually. All tests were two-sided and p values less than 0.05 were considered statistically significant.

**References**

1. Hein, S. et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. *Circulation* **107**, 984–91 (2003).
2. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B. & Castelli, W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N. Engl. J. Med.* **322**, 1561–6 (1990).
3. Dweck, M. R. et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. *J. Am. Coll. Cardiol.* **58**, 1271–9 (2011).
4. Gutiérrez, O. M. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation* **119**, 2545–52 (2009).
5. Mirza, M. A. L., Larsson, A., Melhus, H., Lind, L. & Larsson, T. E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. *Atherosclerosis* **207**, 546–51 (2009).
6. Araki, J. et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. *Kidney Int.** **83**, 160–166 (2013).
7. Andrukhova, O. et al. FGF23 regulates renal sodium handling and blood pressure. *EMBO Mol. Med.* **6**, 744–59 (2014).
8. Andrukhova, O. et al. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. *EMBO J.* **33**, 229–46 (2014).
9. Shimada, T. et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. *J. Clin. Invest.* **113**, 561–8 (2004).
10. Andrukhova, O., Slavic, S., Odorfer, K. I. & Erben, R. G. Experimental Myocardial Infarction Uregulates Circulating Fibroblast Growth Factor 23. *J. Bone Miner. Res.* **30**, 1831–9 (2015).
11. Yan, L. & Bowman, M. A. H. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23. *Inflamm. cell Signal.* **1** (2014).
12. Bansal, S. et al. Spleen contributes significantly to circulating levels of fibroblast growth factor23 in response to lipopolysaccharide-induced inflammation. *Nephrol. Dial. Transplant* gfw376 doi:10.1093/ndt/gfw376 (2016).
13. van Vooroij, N. A. et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. *Nephrol. Dial. Transplant.* **29**, 1525–1532 (2014).
14. Zanchi, C. et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. *PLoS One* **8**, e70775 (2013).


the experiments. S.S., M.M., N.K., A.B., and O.A. analysed the data. S.S., R.G.E. and O.A. wrote the manuscript. S.S., R.G.E. and O.A. conceived and designed the study. S.S., K.F., M.M., N.K., A.B., U.Z. and S.H. performed the work.

work was supported by a grant from the Austrian Science Fund (FWF P 26534-B13) to O.A.

Acknowledgements
We are thankful to Alexandra Petric, Soleman Sagsary and Claudia Bergow for excellent technical support. This work was supported by a grant from the Austrian Science Fund (FWF P 26534-B13) to O.A.

Author Contributions
S.S., R.G.E. and O.A. conceived and designed the study. S.S., K.F., M.M., N.K., A.B., U.Z. and S.H. performed the experiments. S.S., M.M., N.K., A.B., and O.A. analysed the data. S.S., R.G.E. and O.A. wrote the manuscript.
